Inhibition of IL-1β leads to a decrease in the inflammatory process in pancreatic islets, and a reduction in glucose levels which results in an improvement of vascular complications and prevents the conversion of prediabetes to clinically expressed T2DM (Furmanova et al. 2019). Here, IL1B is linked to type 2 diabetes mellitus.